Core Insights - Enwei Pharmaceutical (301331) reported a total revenue of 449 million yuan for the first half of 2025, marking a year-on-year increase of 15.73% and a net profit attributable to shareholders of 38.34 million yuan, up 113.8% from the previous year [1] - The company's gross profit margin decreased to 49.1%, down 5.35% year-on-year, while the net profit margin increased significantly to 8.54%, up 84.74% [1] - Accounts receivable rose significantly, with a year-on-year increase of 48.13%, indicating potential liquidity concerns [1][3] Financial Performance - Total revenue for 2025 was 449 million yuan, compared to 388 million yuan in 2024, reflecting a growth of 15.73% [1] - Net profit attributable to shareholders reached 38.34 million yuan, a substantial increase of 113.8% from 17.93 million yuan in 2024 [1] - The company's operating cash flow per share decreased to 0.73 yuan, down 16.71% year-on-year [1] Cost and Efficiency Metrics - The total of selling, administrative, and financial expenses was 172 million yuan, accounting for 38.22% of revenue, a decrease of 12.2% compared to the previous year [1] - The return on invested capital (ROIC) for the previous year was 3.04%, indicating weak capital returns, while the historical median ROIC since listing is 17.36% [2] - The net profit margin improved to 8.54%, up from 4.62% in the previous year, suggesting better cost management [1][2] Business Model and Market Dynamics - The company's performance is primarily driven by marketing efforts, necessitating a deeper analysis of the underlying factors [3] - In 2024, the company experienced a decline in offline sales revenue, attributed to high inventory levels of cold medications from 2023 that needed to be cleared [3] - The market demand for the company's core product, Huoxiang Zhengqi Decoction, fell short of expectations due to delayed seasonal demand and other factors [3]

Group 1: Company Performance Overview - The company expects a double-digit revenue growth in 2025, with net profit matching revenue growth levels [3] - In Q1, the incidence of flu and respiratory diseases decreased compared to last year, leading to a slight adjustment in performance due to high base effects [2] - The CHC (Consumer Health Care) business is anticipated to have market opportunities in categories such as cold, skin, gastrointestinal, and orthopedics throughout the year [2] Group 2: CHC Business Development - The CHC business has entered a multi-category development phase, expanding beyond the core three categories to include pediatrics, orthopedics, liver and gallbladder, and gynecology [4] - The company aims to enhance its product line and market share in pediatric cold medications despite facing some pressure [4] - New products like the vitamin D drops are being introduced to support pediatric category growth [4] Group 3: Prescription Drug Strategy - The prescription drug business is developing steadily, with a focus on adapting to policy changes such as centralized procurement [6] - The company aims to increase the proportion of innovative drugs in its prescription drug portfolio [7] - The integration with Tianjin Pharmaceutical is expected to enhance the company's brand influence in the medical sector [7] Group 4: Online Business Growth - The company has seen rapid growth in its online business, targeting a 10% share by 2025 [8] Group 5: Mergers and Acquisitions - The company plans to pursue both internal and external growth strategies, focusing on mergers and acquisitions in strategic emerging industries [9] Group 6: Shareholder Engagement and Dividends - The company has a stable cash dividend ratio of 50% and aims to enhance shareholder satisfaction through its incentive plans [10] Group 7: Future Integration with Tianjin Pharmaceutical - The focus will be on innovation-driven business development in key therapeutic areas, enhancing R&D capabilities, and fostering collaboration between Tianjin Pharmaceutical and the company [12] Group 8: Formula Granules Business Outlook - The formula granules business is expected to achieve recovery growth in 2024 and maintain growth in 2025, despite being affected by policy changes [13]

编号：20250528 恩威医药股份有限公司投资者关系活动记录表 | | 院、诊所）及电商渠道进行销售，公司专门成立了销售二部 | | | | | --- | --- | --- | --- | --- | | | 负责开拓第三终端渠道业务。谢谢! | | | | | | 问题 6：公司大股东增持股份计划目前实施进展如何 | | | | | | 了？ | | | | | | 答：公司控股股东一致行动人成都杰威企业管理有限公 | | | | | | 司股份增持计划目前正在实施之中，公司将敦促成都杰威按 | | | | | | 期完成增持计划并及时履行相关信息披露义务。谢谢! | | | | | 附件清单（如有） | 无 | | | | | 日期 | 日星期三 2025 5 | 年 | 月 | 28 | | | ☑特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 宁银理财 徐厚犇 | | 人员姓名 | 惠升基金 ...